Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease

Vaysse, Thibaut; Bourrier, Anne; Amiot, Aurélien; Grimaud, Jean–Charles; Peyrin–Biroulet, Laurent; Zallot, Camille; Bigard, Marc‐André; Filippi, Jérôme; Hébuterne, Xavier; Pariente, Benjamin; Nachury, Maria; Desreumaux, Pierre; Roblin, Xavier; Tedesco, Émilie Del; Buisson, Anthony; Bommelaer, Gilles; Stefănescu, Carmen; Boureille, Arnaud; Trang-Poisson, Caroline; Altwegg, Romain; Marteau, Philippe; Dray, Xavier; Carbonnel, Franck; Seksik, Philippe; Beaugerie, Laurent; Cosnes, Jacques; Sokol, Harry; Landman, Cécilia; Nancey, Stéphane; Boschetti, Gilles; Laharie, David; Poullenot, Florian; Allez, Matthieu; Gornet, Jean–Marc; Baudry, Clautilde; Savoye, Guillaume; Moreau, Jacques; Gagniere, Charlotte; Vuitton, Lucine; Koch, Stéphane; Viennot, Stéphanie; Aubourg, Alexandre; Picon, Laurence; Pelletier, Anne-Laure; Sickersen, Gaelle; Bouguen, Guillaume; Abitbol, Véred; Chaussade, Stanislas; Bouhnik, Yoram; Nahon, Stéphane; Winkfield, Betsy; Brixi-Benmansour, Hedia; Gincul, Rodica; Barberis, Jean-Christophe; Bonaz, Bruno; Michiels, Christophe; Zerbib, F.; Beauregard, Marie Bourrier de; Locher, Christophe; Davin-Couve, Sophie; Poirette, Armelle; Guillem, Laurence; Stetiu-Mocanu, Monica; Beorchia, S.; Qaddi, J. Al

doi:10.1016/j.cgh.2016.02.016

Cited by 164 publications

(99 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In both diseases, the clinical remission rate at week 6 was about 30% and the steroid-free remission rate was about 20%. 222 The efficacy was modest, but still clinically important given the highly refractory profile of this cohort of patients who had previously not responded to anti-TNF therapy.…”

Section: Malignancy and Infectionmentioning

confidence: 91%

Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease

Cohen

Sachar

2017

BMJ

111

View full text Add to dashboard Cite

The treatment of inflammatory bowel disease (IBD)-ulcerative colitis (UC) and Crohn's disease (CD)-has evolved beyond surgery with the introduction of biologic agents, primarily antibodies against mediators of inflammation and cell attraction. Anti-tumor necrosis factor (TNF) agents have been the first line treatment for moderate to severe ulcerative colitis and Crohn's disease for more than 15 years. During that time much has been learnt about how best to use these agents. This review will assess the evidence on how to optimize the use of anti-TNF agents; when and how to start treatment; how to monitor treatment and when to de-escalate it; and the potential adverse effects of these drugs. New and emerging treatments such as anti-attractants, anti-interleukins, and Janus kinase (JAK) inhibitors will also be discussed.

show abstract

Section: Malignancy and Infectionmentioning

confidence: 91%

Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease

Cohen

Sachar

2017

BMJ

111

View full text Add to dashboard Cite

show abstract

“…The adverse effects were comparable between the vedolizumab group and placebo group in most studies. No cases of progressive multifocal leukoencephalopathy have been reported in previous studies [50][51][52][53][54].…”

Section: Vedolizumabmentioning

confidence: 91%

“…Thus, vedolizumab may be useful for patients who are not responsive to anti-TNF treatment. Other cohort studies also indicated a relatively high clinical response (50-53 % at week 14) [52,53] or marked decreases in the partial Mayo score at week 6 [54], which was observed although the patients had not been randomized. The adverse effects were comparable between the vedolizumab group and placebo group in most studies.…”

Section: Vedolizumabmentioning

confidence: 96%

Recent trends and future directions for the medical treatment of ulcerative colitis

Mizuno

Nanki

Sugimoto

et al. 2016

Clin J Gastroenterol

View full text Add to dashboard Cite

Recently, several medical treatments for ulcerative colitis (UC) have been developed, including 5-aminosalicylic acids (5-ASAs), corticosteroids, thiopurine, calcineurin inhibitors, and anti-tumor necrosis factor (TNF) a treatments. Treatment options including calcineurin inhibitors and anti-TNF treatment for refractory UC are discussed in this article. Furthermore, upcoming treatments are introduced, such as golimumab, vedolizumab, AJM300, tofacitinib. Budesonide foamwill be used as one treatment option in patients with distal colitis. Herbal medicine, such as Qing-Dai is also effective for active UC and may be useful for patients who are refractory to antiTNFa treatments. In the near future, physicians will able to use many different treatments for UC patients. However, we should not forget 5-ASA and corticosteroids as the fundamental treatments for UC patients.

show abstract

“…Importantly, the efficacy of vedolizumab for treatment of anti-TNF-resistant CD appears to be quite modest [Sandborn et al 2013, Côté-Daigneault et al 2015. In real-world cohorts of patients with CD or ulcerative colitis (UC) whose disease has failed to respond to previous anti-TNF therapy, approximately one third of patients achieved steroid-free clinical remission after 14 weeks of treatment with vedolizumab [Amiot et al 2016;Baumgart et al 2016]. This emphasizes the need for novel and effective agents.…”

Section: Introductionmentioning

confidence: 99%

Ustekinumab in Crohn’s disease: evidence to date and place in therapy

Engel

Kopylov

2016

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Crohn's disease (CD) is an inflammatory bowel disease (IBD) with uncertain etiology. Biologic agents have revolutionized the treatment of CD but nonresponders remain a challenge. Ustekinumab is an interleukin 12/23p40 inhibitor that was recently found effective in treating CD. We reviewed the current literature regarding the efficacy of ustekinumab in treating CD and concluded that ustekinumab is a novel, promising and relatively safe agent for the treatment of moderate to severe CD. Additional data from randomized controlled studies and real-life cohorts are pending.

show abstract

Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease

Abstract: In a cohort of patients with CD or UC who failed previous anti-tumor necrosis factor therapy, approximately one third of patients achieved steroid-free clinical remission after 14 weeks of induction therapy with vedolizumab. This agent had an acceptable safety profile in these patients.

Cited by 164 publications

References 21 publications

Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease

Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease

Recent trends and future directions for the medical treatment of ulcerative colitis

Ustekinumab in Crohn’s disease: evidence to date and place in therapy

Contact Info

Product

Resources

About